Segments (Tables)

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Information regarding our geographic activities

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended September 30,						For the nine months ended September 30,
(In thousands)	2014			2013			2014			2013
Product revenues:
Pharmaceuticals	$	17,291		$	16,563		$	58,510		$	50,708
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	17,291		$	16,563		$	58,510		$	50,708
Revenue from services:
Pharmaceuticals	$	—		$	—		$	—		$	—
Diagnostics	2,422			2,710			6,426			8,870
Corporate	60			60			180			180
	$	2,482		$	2,770		$	6,606		$	9,050
Revenue from transfer of intellectual property:
Pharmaceuticals	$	—		$	913		$	285		$	14,720
Diagnostics	—			395			191			1,360
Corporate	—			—			—			—
	$	—		$	1,308		$	476		$	16,080
Operating (loss) income:
Pharmaceuticals	$	(34,480	)	$	(11,126	)	$	(71,421	)	$	(7,171	)
Diagnostics	(6,738		)	(399		)	(20,621		)	(16,783		)
Corporate	(6,384		)	(6,606		)	(19,557		)	(17,393		)
Less: Operating loss attributable to noncontrolling interests	(599		)	(879		)	(1,762		)	(2,419		)
	$	(48,201	)	$	(19,010	)	$	(113,361	)	$	(43,766	)
Depreciation and amortization:
Pharmaceuticals	$	1,925		$	2,020		$	6,061		$	5,417
Diagnostics	1,729			1,717			5,136			5,110
Corporate	24			31			72			121
	$	3,678		$	3,768		$	11,269		$	10,648
Revenues:
United States	$	2,482		$	4,078		$	7,082		$	25,130
Chile	7,622			7,993			22,758			24,216
Spain	4,414			4,026			16,230			13,503
Israel	3,710			3,099			14,563			9,666
Mexico	1,528			1,445			4,905			3,323
Other	17			—			54			—
	$	19,773		$	20,641		$	65,592		$	75,838

(In thousands)	September 30, 2014		December 31, 2013
Assets:
Pharmaceuticals	$	1,061,168	$	1,065,033
Diagnostics	109,048		116,944
Corporate	125,026		209,539
	$	1,295,242	$	1,391,516
Goodwill:
Pharmaceuticals	$	173,804	$	175,408
Diagnostics	50,965		50,965
Corporate	—		—
	$	224,769	$	226,373